We want physicians and patients to make informed decisions about the medicines they choose. That’s why we’re committed to supporting awareness and education about biologics, including biosimilars, at every level.
In addition to providing industry education, we also partner with providers, nurses, and advocacy groups to foster learning and knowledge sharing.
Since the first biosimilar entered the US marketplace in 2015, biosimilars have gained significant share in the majority of therapeutic areas where they have been introduced. With 22 biosimilars available in the US as of September 2022, the US marketplace is poised to see further growth in biosimilars approved to date, and welcome many new biosimilars in the years to come.
We promote access to all our medicines by investing in reimbursement services to make sure that tangible value also comes with every medicine. We’re continuously striving to make choosing an Amgen Biosimilar a better experience for patients and their finances.
Amgen leads with action by investing in industry-leading support, education programs, and reimbursement services to make sure holistic value is integrated into every medicine.
Payers often endorse the preferences of prescribers when choosing biosimilars for their formularies, and prescribers often consider Amgen because of the comprehensive patient support services that come with every one of our medicines.
Choosing Amgen Biosimilars helps physicians, patients, and all partners to have access to comprehensive services.